Recurrent epimutations activate gene body promoters in primary glioblastoma

Genome Research

Volumn 24, Issue 5, 2014, Pages 761-774

  Nagarajan, Raman P ^a   Zhang, Bo ^b   Bell, Robert J A ^a   Johnson, Brett E ^a   Olshen, Adam B ^a   Sundaram, Vasavi ^b   Li, Daofeng ^b   Graham, Ashley E ^c   Diaz, Aaron ^d   Fouse, Shaun D ^a   Smirnov, Ivan ^a   Song, Jun ^d   Paris, Pamela L ^d   Wang, Ting ^b   Costello, Joseph F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; PROTEIN P73; DNA BINDING PROTEIN; GLI3 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; NERVE PROTEIN; NUCLEAR PROTEIN; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

5' UNTRANSLATED REGION; ARTICLE; CARCINOGENESIS; CHROMOSOME 5P; CPG ISLAND; DNA METHYLATION; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; GLI3 GENE; GLIOBLASTOMA; HISTONE METHYLATION; HUMAN; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; TELOMERE; TERT GENE; TP73 GENE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUTATION; TRANSCRIPTION INITIATION;

CPG ISLANDS; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; TELOMERASE; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEINS;

EID: 84899893679     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.164707.113     Document Type: Article

References (79)

1. Berman BP, Weisenberger DJ, Aman JF, Hinoue T, Ramjan Z, Liu Y, Noushmehr H, Lange CPE, van Dijk CM, Tollenaar RAEM, et al. 2011. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear laminaassociated domains. Nat Genet 44: 40-46.
2. Bernstein BE, Stamatoyannopoulos JA, Costello JF, Ren B, Milosavljevic A, Meissner A, Kellis M, Marra MA, Beaudet AL, Ecker JR, et al. 2010. The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol 28: 1045-1048.
3. Cadieux B, Ching TT, VandenBerg SR, Costello JF. 2006. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res 66: 8469-8476.
4. Cho M, Uemura H, Kim SC, Kawada Y, Yoshida K, Hirao Y, Konishi N, Saga S, Yoshikawa K. 2001. Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma. Br J Cancer 85: 563-567.
5. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, et al. 2000. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24: 132-138.
6. Cui H, Onyango P, Brandenburg S,Wu Y, Hsieh C-L, Feinberg AP. 2002. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 62: 6442-6446.
7. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. 1996. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci 93: 7149-7153.
8. Diaz A, Nellore A, Song JS. 2012. CHANCE: comprehensive software for quality control and validation of ChIP-seq data. Genome Biol 13: R98.
9. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, et al. 2012. Landscape of transcription in human cells. Nature 489: 101-108.
10. The ENCODE Project Consortium. 2012. An integrated encyclopedia of DNA elements in the human genome. Nature 489: 57-74.
11. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N,Ward LD, Epstein CB, Zhang X, Wang L, Issner R, Coyne M, et al. 2011. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473: 43-49.
12. Faulkner GJ, Kimura Y, Daub CO, Wani S, Plessy C, Irvine KM, Schroder K, Cloonan N, Steptoe AL, Lassmann T, et al. 2009. The regulated retrotransposon transcriptome of mammalian cells. Nat Genet 41: 563-571.
13. Feinberg AP, Vogelstein B. 1983. Hypomethylation distinguishes genes of some human cancers fromtheir normal counterparts. Nature 301: 89-92.
14. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW, Ehrlich M. 1983. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 11: 6883-6894.
15. Grunau C, Clark SJ, Rosenthal A. 2001. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res 29: E65.
16. Hansen KD, TimpW, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, Wen B,Wu H, Liu Y, Diep D, et al. 2011. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 43: 768-775.
17. Harris RA, Wang T, Coarfa C, Nagarajan RP, Hong C, Downey SL, Johnson BE, Fouse SD, Delaney A, Zhao Y, et al. 2010. Comparison of sequencingbased methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol 28: 1097-1105.
18. Hasegawa K, Yoshida T, Matsumoto K, Katsuta K,Waga S, Sakakura T. 1997. Differential expression of tenascin-C and tenascin-X in human astrocytomas. Acta Neuropathol 93: 431-437.
19. Hoffman RM. 1984. Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis. A review and synthesis. Biochim Biophys Acta 738: 49-87.
20. Hon GC, Hawkins RD, Caballero OL, Lo C, Lister R, Pelizzola M, Valsesia A, Ye Z, Kuan S, Edsall LE, et al. 2012. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res 22: 246-258.
21. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, et al. 2013. TERT promoter mutations in familial and sporadic melanoma. Science 339: 959-961.
22. Hrdlickova R, Nehyba J, Bose HR Jr. 2012. Alternatively spliced telomerase reverse transcriptase variants lacking telomerase activity stimulate cell proliferation. Mol Cell Biol 32: 4283-4296.
23. Hsu F, Kent WJ, Clawson H, Kuhn RM, Diekhans M, Haussler D. 2006. The UCSC Known Genes. Bioinformatics 22: 1036-1046.
24. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. 2013. Highly recurrent TERT promoter mutations in human melanoma. Science 339: 957-959.
25. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. 2002. Possible oncogenic potential of DNp73: a newly identified isoform of human p73. Cancer Res 62: 636-641.
26. Ito Y, Koessler T, Ibrahim AE, Rai S, Vowler SL, Abu-Amero S, Silva AL, Maia AT, Huddleston JE, Uribe-Lewis S, et al. 2008. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer. HumMol Genet 17: 2633-2643.
27. James SR, Link PA, Karpf AR. 2006. Epigenetic regulation of X-linked cancer/ germline antigen genes by DNMT1 and DNMT3b. Oncogene 25: 6975-6985.
28. Jin S-G, Kadam S, Pfeifer GP. 2010. Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine. Nucleic Acids Res 38: e125.
29. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, et al. 2013. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343: 189-193.
30. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. 2002. The Human Genome Browser at UCSC. Genome Res 12: 996-1006.
31. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, et al. 2013. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci 110: 6021-6026.
32. Kulis M, Heath S, Bibikova M, Queiros AC, Navarro A, Clot G, Martinez-Trillos A, Castellano G, Brun-Heath I, Pinyol M, et al. 2012. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 44: 1236-1242.
33. Laird PW. 2010. Principles and challenges of genomewide DNA methylation analysis. Nat Rev Genet 11: 191-203.
34. Lamprecht B,Walter K, Kreher S, Kumar R, Hummel M, Lenze D, Kochert K, Bouhlel MA, Richter J, Soler E et al. 2010. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med 16: 571-579.
35. Langmead B. 2010. Aligning short sequencing reads with Bowtie. Curr Protoc Bioinformatics 32: 111-117.
36. Le S, Zhu JJ, Anthony DC, Greider CW, Black PM. 1998. Telomerase activity in human gliomas. Neurosurgery 42: 1120-1124; discussion 1124-1125.
37. Li LC, Dahiya R. 2002. MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431.
38. Li H, Durbin R. 2010. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26: 589-595.
39. Lotsch D, Ghanim B, Laaber M, Wurm G, Weis S, Lenz S, Webersinke G, Pichler J, BergerW, Spiegl-Kreinecker S. 2013. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro Oncol 15: 423-432.
40. Lynch VJ, Leclerc RD, May G, Wagner GP. 2011. Transposon-mediated rewiring of gene regulatory networks contributed to the evolution of pregnancy in mammals. Nat Genet 43: 1154-1159.
41. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF, Ropero S, Schackert G, Esteller M. 2009. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 4: 255-264.
42. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD, Johnson BE, Hong C, Nielsen C, Zhao Y, et al. 2010. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 466: 253-257.
43. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB,Wenger AM, Bejerano G. 2010. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol 28: 495-501.
44. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, Olson JJ, Mikkelsen T, Lehman N, Aldape K, et al. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
45. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, Zhang X, Bernstein BE, Nusbaum C, Jaffe DB, et al. 2008. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454: 766-770.
46. Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, Wong M, Sloan CA, Rosenbloom KR, Roe G, Rhead B, et al. 2013. The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res 41: D64-D69.
47. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, et al. 1997. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795.
48. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M, Schneider C. 2006. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci 103: 11160-11165.
49. Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V, Dezso Z, Mulvey L, Macconaill LE, Winckler W, et al. 2008. Genomewide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res 68: 9532-9540.
50. Noushmehr H,Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al. 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
51. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W, et al. 2007. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39: 237-242.
52. Oster B, Linnet L, Christensen LL, Thorsen K, Ongen H, Dermitzakis ET, Sandoval J, Moran S, Esteller M, Hansen TF, et al. 2013. Non-CpG island promoter hypomethylation and miR-149 regulate the expression of SRPX2 in colorectal cancer. Int J Cancer 132: 2303-2315.
53. Park J-I, Venteicher AS, Hong JY, Choi J, Jun S, Shkreli M, ChangW, Meng Z, Cheung P, Ji H, et al. 2009. Telomerase modulates Wnt signalling by association with target gene chromatin. Nature 460: 66-72.
54. Pruitt KD, Tatusova T, Maglott DR. 2007. NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 35: D61-D65.
55. Rajaraman P, Melin BS,Wang Z, McKean-Cowdin R, Michaud DS,Wang SS, Bondy M, Houlston R, Jenkins RB, Wrensch M, et al. 2012. Genomewide association study of glioma and meta-analysis. Hum Genet 131: 1877-1888.
56. Rao M, Chinnasamy N, Hong JA, Zhang Y, Zhang M, Xi S, Liu F, Marquez VE, Morgan RA, Schrump DS. 2011. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res 71: 4192-4204.
57. Robinson MD, Statham AL, Speed TP, Clark SJ. 2010. Protocol matters: which methylome are you actually studying? Epigenomics 2: 587-598.
58. Rohde C, Zhang Y, Reinhardt R, Jeltsch A. 2010. BISMA-fast and accurate bisulfite sequencing data analysis of individual clones from unique and repetitive sequences. BMC Bioinformatics 11: 230.
59. Rollins RA, Haghighi F, Edwards JR, Das R, Zhang MQ, Ju J, Bestor TH. 2006. Large-scale structure of genomic methylation patterns. Genome Res 16: 157-163.
60. Rosenbloom KR, Dreszer TR, Long JC, Malladi VS, Sloan CA, Raney BJ, Cline MS, Karolchik D, Barber GP, Clawson H, et al. 2012. ENCODE wholegenome data in the UCSC Genome Browser: update 2012. Nucleic Acids Res 40: D912-D917.
61. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV, Conforti F, Velletri T, Mastino A, Mak TW, et al. 2011. p73 in cancer. Genes Cancer 2: 491-502.
62. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE, et al. 2007. Polycombmediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39: 232-236.
63. Shay JW, Bacchetti S. 1997. A survey of telomerase activity in human cancer. Eur J Cancer 33: 787-791.
64. Shen JJ, Zhang NR. 2012. Change-point model on nonhomogeneous Poisson processes with application in copy number profiling by nextgeneration DNA sequencing. Ann Appl Stat 6: 476-496.
65. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, Malmer B, Simon M, Marie Y, Boisselier B, Delattre J-Y, et al. 2009. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41: 899-904.
66. Venkatraman ES, Olshen AB. 2007. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23: 657-663.
67. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
68. Wang T, Zeng J, Lowe CB, Sellers RG, Salama SR, Yang M, Burgess SM, Brachmann RK, Haussler D. 2007. Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53. Proc Natl Acad Sci 104: 18613-18618.
69. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, Schubeler D. 2007. Distribution, silencing potential and evolutionary impact of promoterDNAmethylation in the human genome. NatGenet 39: 457-466.
70. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, et al. 2007. Epigenetic stem cell signature in cancer. Nat Genet 39: 157-158.
71. Wild L, Flanagan JM. 2010.Genome-wide hypomethylation in cancer may be a passive consequence of transformation. Biochim Biophys Acta 1806: 50-57.
72. Wolff EM, Byun HM, Han HF, Sharma S, NicholsPW, Siegmund KD, Yang AS, Jones PA, Liang G. 2010. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet 6: e1000917.
73. Wrensch M, Jenkins RB, Chang JS, Yeh R-F, Xiao Y, Decker PA, Ballman KV, Berger M, Buckner JC, Chang S, et al. 2009. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 41: 905-908.
74. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D, Pfeifer GP. 2010. CpG island hypermethylation in human astrocytomas. Cancer Res 70: 2718-2727.
75. Xie M, Hong C, Zhang B, Lowdon RF, Xing X, Li D, Zhou X, Lee HJ, Maire CL, Ligon KL, et al. 2013. DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. Nat Genet 45: 836-841.
76. Zardo G, Tiirikainen MI, Hong C, Misra A, Feuerstein BG, Volik S, Collins CC, Lamborn KR, Bollen A, Pinkel D, et al. 2002. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nat Genet 32: 453-458.
77. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, LiW, et al. 2008. Model-based analysis of ChIPSeq (MACS). Genome Biol 9: R137.
78. Zhang B, Zhou Y, Lin N, Lowdon RF, Hong C, Nagarajan RP, Cheng JB, Li D, Stevens M, Lee HJ, et al. 2013. Functional DNA methylation differences between tissues, cell types, and across individuals discovered using the M and M algorithm. Genome Res 23: 1522-1540.
79. Zheng S, Houseman EA, Morrison Z,Wrensch MR, Patoka JS, RamosC, Haas-Kogan DA, McBride S, Marsit CJ, Christensen BC, et al. 2011. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro Oncol 13: 280-289.